Читать книгу Biopharmaceutics - Группа авторов - Страница 78

1 [1] Kerns, E.H., Di, L., and Carter, G.T. (2008). In vitro solubility assays in drug discovery. Current Drug Metabolism 9 (9): 879–885.

2 [2] Di, L., Kerns, E.H., and Carter, G.T. (2009). Drug‐like property concepts in pharmaceutical design. Current Pharmaceutical Design 15 (19): 2184–2194.

3 [3] Di, L., Fish, P.V., and Mano, T. (2012). Bridging solubility between drug discovery and development. Drug Discovery Today 17 (9): 486–495.

4 [4] Bergström, C.A.S. and Larsson, P. (2018). Computational prediction of drug solubility in water‐based systems: qualitative and quantitative approaches used in the current drug discovery and development setting. International Journal of Pharmaceutics 540 (1): 185–193.

5 [5] Bauer, J., Spanton, S., Henry, R. et al. (2001). Ritonavir: an extraordinary example of conformational polymorphism. Pharmaceutical Research 18 (6): 859–866.

6 [6] Markopoulos, C., Andreas, C.J., Vertzoni, M. et al. (2015). In‐vitro simulation of luminal conditions for evaluation of performance of oral drug products: choosing the appropriate test media. European Journal of Pharmaceutics and Biopharmaceutics 93: 173–182.

7 [7] Galia, E., Nicolaides, E., Hörter, D. et al. (1998). Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharmaceutical Research 15 (5): 698–705.

8 [8] Vertzoni, M., Fotaki, N., Nicolaides, E. et al. (2004). Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. Journal of Pharmacy and Pharmacology 56 (4): 453–462.

9 [9] Vertzoni, M., Dressman, J., Butler, J. et al. (2005). Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. European Journal of Pharmaceutics and Biopharmaceutics 60 (3): 413–417.

10 [10] Jantratid, E., Janssen, N., Reppas, C., and Dressman, J.B. (2008). Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharmacuetical Research 25 (7): 1663.

11 [11] Vertzoni, M., Diakidou, A., Chatzilias, M. et al. (2010). Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility. Pharmaceutical Research 27 (10): 2187–2196.

12 [12] Amaral Silva, D., Al‐Gousous, J., Davies, N.M. et al. (2019). Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics 142: 8–19.

13 [13] Wiedmann, T.S. and Kamel, L. (2002). Examination of the solubilization of drugs by bile salt micelles. Journal of Pharmaceutical Sciences 91 (8): 1743–1764.

14 [14] Fagerberg, J.H., Tsinman, O., Sun, N. et al. (2010). Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Molecular Pharmaceutics 7 (5): 1419–1430.

15 [15] Fatouros, D.G., Walrand, I., Bergenstahl, B., and Müllertz, A. (2009). Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products. Pharmaceutical Research 26 (2): 361.

16 [16] Kleberg, K., Jacobsen, F., Fatouros, D.G., and Müllertz, A. (2010). Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. Journal of Pharmaceutical Sciences 99 (8): 3522–3532.

17 [17] Streng, W.H., Hsi, S.K., Helms, P.E., and Tan, H.G.H. (1984). General treatment of pH‐solubility profiles of weak acids and bases and the effects of different acids on the solubility of a weak base. Journal of Pharmaceutical Sciences 73 (12): 1679–1684.

18 [18] Newman, A. (2017). Rational design for amorphous solid dispersions. In: Developing Solid Oral Dosage Forms, 2e (eds. Y. Qiu, Y. Chen, G.G.Z. Zhang, et al.), 497–518. Boston: Academic Press.

19 [19] van der Vossen, A.C., van der Velde, I., Smeets, O.S.N.M. et al. (2017). Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug. European Journal of Pharmaceutical Sciences 100: 205–210.

20 [20] Saokham, P., Muankaew, C., Jansook, P., and Loftsson, T. (2018). Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules (Basel, Switzerland) 23 (5): 1161. https://doi.org/10.3390/molecules23051161. PMID: 29751694; PMCID: PMC6099580.